Nancy Luo1, Nicholas G Ballew2, Emily C O'Brien3, Melissa A Greiner2, Pamela N Peterson4, Bradley G Hammill2, N Chantelle Hardy2, Warren K Laskey5, Paul A Heidenreich6, Chun-Lan Chang7, Adrian F Hernandez8, Lesley H Curtis3, Robert J Mentz8, Gregg C Fonarow9. 1. Department of Medicine, Duke University School of Medicine, Durham, NC, United States; Duke Clinical Research Institute, Durham, NC, United States. Electronic address: nancy.luo@duke.edu. 2. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States. 3. Duke Clinical Research Institute, Durham, NC, United States; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, United States. 4. Denver Health Medical Center, Denver, CO, United States; University of Colorado, Anschutz Medical Center, Aurora, CO, United States. 5. Division of Cardiology, University of New Mexico School of Medicine, Albuquerque, NM, United States. 6. Department of Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, United States. 7. Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States. 8. Department of Medicine, Duke University School of Medicine, Durham, NC, United States; Duke Clinical Research Institute, Durham, NC, United States. 9. Ahmanson-UCLA Cardiomyopathy Center, University of California, Los Angeles, CA, United States.
Abstract
BACKGROUND: On May 20, 2016, US professional organizations in cardiology published joint treatment guidelines recommending the use of angiotensin-receptor neprilysin inhibitor (ARNI) for eligible patients with heart failure with reduced ejection fraction (HFrEF). Using data from the Get With The Guidelines-Heart Failure registry, we evaluated the early impact of this update on temporal trends in ARNI prescription. METHODS: We analyzed patients with HFrEF who were eligible for ARNI prescription (EF ≤40%, no contraindications) and hospitalized from February 20, 2016, through August 19, 2016-allowing for 13weeks before and after guideline publication. We quantified trends in ARNI use associated with guidelines publication with an interrupted time-series design using logistic regression and accounting for correlations within hospitals using general estimating equation methods. RESULTS: Of 7,200 eligible patient hospitalizations, 51.9% were discharged in the period directly preceding publication of the guidelines, and 48.1% were discharged after. Odds ratios of ARNI prescription at discharge were significantly higher in the postguideline period compared with the preguideline period in adjusted models (adjusted odds ratio 1.29, 95% CI 1.06-1.57, P=.01). However, there was no significant interaction between observed and expected ARNI use after guideline publication (Pinteraction=.14). Results were consistent using a 6-month before and after time frame. CONCLUSIONS: The model suggested a small increase in ARNI use in HF patients being discharged from the hospital immediately after guideline release. However, the publication of national guidelines recommending ARNI use seemed to have little influence on the adoption of this evidence-based medication in the first 3 to 6months.
BACKGROUND: On May 20, 2016, US professional organizations in cardiology published joint treatment guidelines recommending the use of angiotensin-receptor neprilysin inhibitor (ARNI) for eligible patients with heart failure with reduced ejection fraction (HFrEF). Using data from the Get With The Guidelines-Heart Failure registry, we evaluated the early impact of this update on temporal trends in ARNI prescription. METHODS: We analyzed patients with HFrEF who were eligible for ARNI prescription (EF ≤40%, no contraindications) and hospitalized from February 20, 2016, through August 19, 2016-allowing for 13weeks before and after guideline publication. We quantified trends in ARNI use associated with guidelines publication with an interrupted time-series design using logistic regression and accounting for correlations within hospitals using general estimating equation methods. RESULTS: Of 7,200 eligible patient hospitalizations, 51.9% were discharged in the period directly preceding publication of the guidelines, and 48.1% were discharged after. Odds ratios of ARNI prescription at discharge were significantly higher in the postguideline period compared with the preguideline period in adjusted models (adjusted odds ratio 1.29, 95% CI 1.06-1.57, P=.01). However, there was no significant interaction between observed and expected ARNI use after guideline publication (Pinteraction=.14). Results were consistent using a 6-month before and after time frame. CONCLUSIONS: The model suggested a small increase in ARNI use in HF patients being discharged from the hospital immediately after guideline release. However, the publication of national guidelines recommending ARNI use seemed to have little influence on the adoption of this evidence-based medication in the first 3 to 6months.